1. Scrip
  2. >>Business
  3. >>Deals

Lilly To Try ProQR’s RNA-Editing Technology In Liver, Neurology Indications

 
• By Joseph Haas

ProQR’s Axiomer platform can enable single nucleotide RNA editing, an approach that could address thousands of disease-causing genetic mutations, the company says.

Innovation concept presented by a consultant in management on webinar screen
Lilly decides to tap into ProQR's RNA-editing technology

In its second deal around an RNA-based approach to drug development this year, Eli Lilly and Company agreed on 8 September to partner with ProQR Therapeutics N.V. on an effort to develop five novel therapies derived from RNA editing for liver and neurology indications. Lilly is paying the Leiden, the Netherlands-based firm $50m up front - $20m in cash and $30m in equity investment – with potential for up to $1.25bn in milestones to ProQR plus sales royalties.

In May, Lilly unveiled a deal with a similar financial structure – modest upfront payment and significant earnout potential –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

More from Business

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

 
• By Jung Won Shin

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.